Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer
NCT07448493 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 230
Last updated 2026-03-04
Summary
GASTROBRAIN trial is an international (2 countries) observational, multicenter (15 centers) retrospective cohort study designed to investigate local treatment strategies for brain metastases of gastric and esophageal cancer
Conditions
- Gastric Cancer
- Esophageal Cancer
- Brain Metastases
Interventions
- OTHER
-
Combined Local Treatment Modalities
Patients in this cohort received a combination of local treatment approaches. This includes: * NRS with postoperative WBRT; * NRS with postoperative SRT/SRS; * Preoperative SRS followed by NRS; * Combination radiotherapy (SRS and WBRT, SRT and WBRT, SRS and SRT)
- PROCEDURE
-
Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR)
Patients in this cohort underwent neurosurgical resection as the primary local treatment for brain metastases. Surgical approaches include: * En-bloc resection (EBR): gross-total removal of the tumor as a single, intact specimen with no residual disease on postoperative MRI; * Total piecemeal resection (TPR): gross-total removal of the tumor in multiple fragments with no residual disease on postoperative MRI * Subtotal (SPR) or partial (PPR) piecemeal resection: incomplete removal of the tumor, with macroscopic residual disease on postoperative MRI. This includes: * Subtotal resection: 75-90% of tumor volume removed * Partial resection: 30-75% of tumor volume removed * Extent of resection unknown: surgical resection performed, but the precise extent could not be determined from available records
- RADIATION
-
Radiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT)
Patients in this cohort received radiotherapy as the primary local treatment modality for brain metastases. Treatment modalities include: * Stereotactic radiosurgery (SRS): single-fraction, high-precision radiation with a prescribed dose \> 12 Gy; * Staged stereotactic radiosurgery (stSRS): radiosurgery delivered in 2-3 stages, typically 2-4 weeks apart, allowing for tumor volume reduction between stages; * Stereotactic radiotherapy (hypofractionated) (SRT): stereotactic radiation delivered in multiple fractions, including: * 3 fractions (single dose 7-9 Gy, total dose 21-27 Gy); * 5 fractions (single dose 6-7 Gy, total dose 30-35 Gy); * 7 fractions (single dose 5 Gy, total dose 35 Gy). * Whole-brain radiotherapy (WBRT): conventional fractionated radiation to the entire brain.
- OTHER
-
No Local Treatment
Patients in this cohort did not receive any local treatment for their brain metastases. This may include patients receiving best supportive care (BSC) (typically includes the administration of corticosteroids for symptomatic control of peritumoral edema and neurological symptoms) or systemic therapy alone. Reasons for not receiving local treatment may include poor performance status, extensive intracranial disease, or patient preference.
Sponsors & Collaborators
-
Blokhin's Russian Cancer Research Center
lead OTHER
Principal Investigators
-
David Khalafyan, MD · Blokhin's Russian Cancer Research Center
-
Alexey Tryakin, MD, PhD, professor · Blokhin's Russian Cancer Research Center
-
Ali Bekyashev, MD, PhD, professor · Blokhin's Russian Cancer Research Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-01
- Primary Completion
- 2027-10-01
- Completion
- 2027-10-01
Countries
- Belarus
- Russia
Study Locations
More Related Trials
-
High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
NCT01378481 ·Status: TERMINATED ·Phase: PHASE1
-
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
NCT01843413 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
NCT01363557 ·Status: TERMINATED ·Phase: NA
-
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
NCT00445588 ·Status: COMPLETED ·Phase: PHASE2
-
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT00305864 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
NCT00004688 ·Status: COMPLETED ·Phase: PHASE2
-
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
NCT01217411 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
NCT04114981 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain
NCT00293358 ·Status: COMPLETED ·Phase: PHASE3
-
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
NCT04197492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
NCT00006388 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
NCT01600742 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
NCT00946673 ·Status: COMPLETED ·Phase: PHASE1
-
GRN1005 for Brain Metastases From Breast or Lung Cancer
NCT01679743 ·Status: WITHDRAWN ·Phase: PHASE2
-
Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
NCT00004146 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
NCT06857006 ·Status: RECRUITING ·Phase: NA
-
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
NCT06806228 ·Status: SUSPENDED ·Phase: PHASE1
-
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
NCT06852001 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
NCT02015117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
NCT00928226 ·Status: COMPLETED ·Phase: NA
-
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
NCT00019578 ·Status: COMPLETED ·Phase: PHASE1
-
Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors
NCT01424839 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
NCT06132945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
NCT04585724 ·Status: WITHDRAWN ·Phase: PHASE1
-
Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00128700 ·Status: COMPLETED ·Phase: PHASE1/PHASE2